You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory Plasma Cell Myeloma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 24, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Actinium Ac 225-DOTA-Daratumumab, Daratumumab,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Actinium Ac 225-DOTA-Daratumumab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
  • +1 more
Jan 5, 2023

Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Plasma Cell Leukemia in Relapse
  • Biological
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital
May 29, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Multiple Myeloma, Plasma Cell Leukemia Trial in Suzhou (CT0594CP)

Recruiting
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • CT0594CP
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
Apr 18, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix (Autologous MUC1-activated T-cells,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Phoenix, Arizona
    Mayo Clinic Hospital in Arizona
Jan 4, 2023

Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial (CAR-T (CAR-GPRC5D))

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • (no location specified)
Feb 26, 2023

Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Mar 23, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Belantamab Mafodotin, Biospecimen

Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Belantamab Mafodotin
  • +6 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Apr 27, 2023

ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma Trial in Atlanta

Active, not recruiting
  • ISS Stage I Plasma Cell Myeloma
  • +4 more
  • Pembrolizumab
  • Radiation Therapy
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
Mar 2, 2022

Multiple Myeloma, Primary Plasma Cell Leukemia Trial in Shanghai (Experimental: CAR-T cells Infusion)

Not yet recruiting
  • Multiple Myeloma
  • Primary Plasma Cell Leukemia
  • Experimental: CAR-T cells Infusion
  • Shanghai, China
    Shanghai Changzheng Hospital
Apr 20, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Ann Arbor, Saint Louis (Dexamethasone, Ixazomib,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
  • +3 more
Jan 6, 2023

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Capivasertib)

Active, not recruiting
Has Results
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 28, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Trametinib

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Aug 13, 2022

Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)

Recruiting
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Human BCMA targeted CAR-NK cells injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 13, 2023

Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix, Jacksonville, Rochester

Recruiting
  • Plasma Cell Myeloma
  • +3 more
  • Bone Marrow Biopsy
  • +3 more
  • Phoenix, Arizona
  • +2 more
Jan 18, 2023

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • YTS104 Cells injection
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 13, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,

Active, not recruiting
Has Results
  • Refractory Plasma Cell Myeloma
  • Recurrent Plasma Cell Myeloma
  • ixazomib citrate
  • +2 more
  • Scottsdale, Arizona
  • +4 more
Mar 28, 2022

Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma Trial in Houston (procedure, drug, other)

Active, not recruiting
  • Plasma Cell Leukemia
  • +3 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 6, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Defactinib

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Defactinib Hydrochloride
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 28, 2022

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Oct 30, 2023

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022